A PBS listing has been recommended for midostaurin (Rydapt) in the treatment of FLT3 mutation positive acute myeloid leukaemia (AML). At its July meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) made a positive recommendation for a Section 100 (Highly Specialised Drugs Program) Authority Required listing of midostaurin for the treatment of patients with newly diagnosed ...
PBS subsidy recommended for AML drug
By Michael Woodhead
21 Aug 2018